183 related articles for article (PubMed ID: 18031247)
41. Toll-like receptors and Type I interferons.
Uematsu S; Akira S
J Biol Chem; 2007 May; 282(21):15319-23. PubMed ID: 17395581
[TBL] [Abstract][Full Text] [Related]
42. The future of toll-like receptor therapeutics.
Parkinson T
Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
[TBL] [Abstract][Full Text] [Related]
43. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides.
Diebold SS; Massacrier C; Akira S; Paturel C; Morel Y; Reis e Sousa C
Eur J Immunol; 2006 Dec; 36(12):3256-67. PubMed ID: 17111347
[TBL] [Abstract][Full Text] [Related]
44. Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma.
Erridge C; Burdess A; Jackson AJ; Murray C; Riggio M; Lappin D; Milligan S; Spickett CM; Webb DJ
Eur J Clin Invest; 2008 Oct; 38(10):713-20. PubMed ID: 18837796
[TBL] [Abstract][Full Text] [Related]
45. Innate immune response to viral infection.
Koyama S; Ishii KJ; Coban C; Akira S
Cytokine; 2008 Sep; 43(3):336-41. PubMed ID: 18694646
[TBL] [Abstract][Full Text] [Related]
46. A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands.
Dowling D; Hamilton CM; O'Neill SM
Cytokine; 2008 Mar; 41(3):254-62. PubMed ID: 18221884
[TBL] [Abstract][Full Text] [Related]
47. Neonatal goats display a stronger TH1-type cytokine response to TLR ligands than adults.
Tourais-Esteves I; Bernardet N; Lacroix-Lamandé S; Ferret-Bernard S; Laurent F
Dev Comp Immunol; 2008; 32(10):1231-41. PubMed ID: 18514862
[TBL] [Abstract][Full Text] [Related]
48. Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know?
O'Neill LA
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):319-27. PubMed ID: 18446139
[TBL] [Abstract][Full Text] [Related]
49. [The investigations of the role of toll-like receptors (TLR) in host response to parasitic infection on the current background regarding TLR in mammals and the model nematode Caenorhabditis elegans].
Wojtkowiak A
Wiad Parazytol; 2007; 53(3):203-11. PubMed ID: 18075152
[TBL] [Abstract][Full Text] [Related]
50. Dynamic control of nucleic-acid-sensing Toll-like receptors by the endosomal compartment.
Miyake K; Saitoh SI; Fukui R; Shibata T; Sato R; Murakami Y
Int Immunol; 2021 Nov; 33(12):835-840. PubMed ID: 34223897
[TBL] [Abstract][Full Text] [Related]
51. Toll-Like receptors (TLRs) and their ligands.
Uematsu S; Akira S
Handb Exp Pharmacol; 2008; (183):1-20. PubMed ID: 18071652
[TBL] [Abstract][Full Text] [Related]
52. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes.
Kim YM; Brinkmann MM; Paquet ME; Ploegh HL
Nature; 2008 Mar; 452(7184):234-8. PubMed ID: 18305481
[TBL] [Abstract][Full Text] [Related]
53. Characterization of the innate immune signalling pathways in hepatocyte cell lines.
Preiss S; Thompson A; Chen X; Rodgers S; Markovska V; Desmond P; Visvanathan K; Li K; Locarnini S; Revill P
J Viral Hepat; 2008 Dec; 15(12):888-900. PubMed ID: 18673429
[TBL] [Abstract][Full Text] [Related]
54. Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing.
Seya T; Matsumoto M; Ebihara T; Oshiumi H
Immunol Rev; 2009 Jan; 227(1):44-53. PubMed ID: 19120474
[TBL] [Abstract][Full Text] [Related]
55. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications.
Guiducci C; Coffman RL; Barrat FJ
J Intern Med; 2009 Jan; 265(1):43-57. PubMed ID: 19093959
[TBL] [Abstract][Full Text] [Related]
56. [Toll-like receptors, a new way of treatment?].
Pedersen CV; Østergaard LJ; Mogensen TH; Paludan SR; Bertelsen LS
Ugeskr Laeger; 2007 Jun; 169(23):2193-8. PubMed ID: 17592684
[TBL] [Abstract][Full Text] [Related]
57. Advances in Antiviral Therapies Targeting Toll-like Receptors.
Shah M; Anwar MA; Kim JH; Choi S
Expert Opin Investig Drugs; 2016; 25(4):437-53. PubMed ID: 26878224
[TBL] [Abstract][Full Text] [Related]
58. Recognition of nucleic acids by Toll-like receptors and development of immunomodulatory drugs.
Kuznik A; Panter G; Jerala R
Curr Med Chem; 2010; 17(18):1899-914. PubMed ID: 20377514
[TBL] [Abstract][Full Text] [Related]
59. Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors.
Talukdar A; Ganguly D; Roy S; Das N; Sarkar D
J Med Chem; 2021 Jun; 64(12):8010-8041. PubMed ID: 34107682
[TBL] [Abstract][Full Text] [Related]
60. TLRs as pharmacological targets for plant-derived compounds in infectious and inflammatory diseases.
Liu X; Zheng J; Zhou H
Int Immunopharmacol; 2011 Oct; 11(10):1451-6. PubMed ID: 21586344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
